Theravance Biopharma, Inc.
A biopharmaceutical company that makes YUPELRI (revefenacin), a once-daily nebulized medicine that helps people with COPD breathe more easily, sold in the US with partner Viatris. It grew out of Theravance, Inc., founded in 1996, which split in 2014 into two public companies, with Theravance Biopharma keeping the respiratory drug pipeline. Its name blends "therapy" and "advance"—fitting for a firm built on advancing medicine.
Bought 2.50M
Granted 888.4K · Sold 50.0K
Granted 360.0K · Sold 65.0K
Granted 52.0K
Granted 287.5K
Granted 292.5K
Granted 330.0K · Sold 45.8K
Granted 239.0K · Sold 139.1K
Granted 141.7K
Granted 19.0K
Granted 46.2K
Granted 46.2K
Granted 46.2K
Granted 9.9K
Granted 46.2K
Granted 40.2K · Sold 74.5K
Granted 48.1K
Granted 33.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Samaha Eli10% owner · 3 transactions | — | 9.51Mas of Aug 2024 | — | 2.50M | — |
| Winningham Rick ECHIEF EXECUTIVE OFFICER, Director · 39 transactions | — | 1.73M | 888.4K | — | 50.0K |
| Pasqualone FrankSVP, CHIEF BUSINESS OFFICER · 1 transaction | -0.9% | 429.8Kas of Nov 2021 | — | — | — |
| Hindman Andrew A.SVP, CHIEF FINANCIAL OFFICER · 8 transactions | +129.8% | 384.7Kas of Nov 2022 | 360.0K | — | 65.0K |
| Pitzer Kenneth RSVP, PROD STRAT & COMM PLNG · 3 transactions | +5.7% | 380.1Kas of Feb 2022 | 52.0K | — | — |
| Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY · 19 transactions | — | 355.2K | 287.5K | — | — |
| Sawaf AzizSVP & CHIEF FINANCIAL OFFICER · 19 transactions | — | 336.8K | 292.5K | — | — |
| Worboys Philip DSVP, RESEARCH & TRANSL SCIENCE · 1 transaction | -1.3% | 330.8Kas of Nov 2021 | — | — | — |
| Graham Richard ASVP, RESEARCH & DEVELOPMENT · 27 transactions | +81.8% | 314.9Kas of Feb 2024 | 330.0K | — | 45.8K |
| Sabesan VijaySVP, TECHNICAL OPERATIONS · 1 transaction | -2.2% | 235.5Kas of Nov 2021 | — | — | — |
| Farnum RhondaSVP, COMM & MEDICAL AFFAIRS · 49 transactions | — | 226.8K | 239.0K | — | 139.1K |
| Miller AineSVP, DEV & HEAD OF IRE OFFICE · 15 transactions | — | 189.8K | 141.7K | — | — |
| Malkiel Burton GDirector · 2 transactions | +19.7% | 115.6Kas of May 2023 | 19.0K | — | — |
| Brady AnnPRESIDENT, TBIL · 2 transactions | -9.5% | 110.3Kas of Feb 2022 | — | — | — |
| Mitchell Dean JDirector · 5 transactions | +90.5% | 97.2K | 46.2K | — | — |
| Smaldone Alsup LaurieDirector · 5 transactions | +132.7% | 81.0K | 46.2K | — | — |
| O'Connor DonalDirector · 6 transactions | +82.2% | 80.2K | 46.2K | — | — |
| Young William DDirector · 1 transaction | +14.5% | 78.0Kas of Apr 2022 | 9.9K | — | — |
| Pakianathan DeepikaDirector · 5 transactions | +258.1% | 64.1K | 46.2K | — | — |
| Broshy EranDirector · 9 transactions | +18% | 60.2K | 40.2K | — | 74.5K |
| Gray SusannahDirector · 6 transactions | — | 48.1K | 48.1K | — | — |
| Grant Jeremy TDirector · 4 transactions | — | 33.0Kas of May 2025 | 33.0K | — | — |
| GSK plcFormer 10% Owner · 1 transaction | — | 0as of Sep 2022 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +2.12M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.